Business Description
Xeris Biopharma Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US98422L1070
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | -0.02 | |||||
Debt-to-Equity | -33.79 | |||||
Debt-to-EBITDA | -9.66 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -1.82 | |||||
Beneish M-Score | -2.4 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 35.5 | |||||
3-Year EBITDA Growth Rate | 54.7 | |||||
3-Year EPS without NRI Growth Rate | 39.8 | |||||
3-Year FCF Growth Rate | 42.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 16.43 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 74.74 | |||||
9-Day RSI | 54.37 | |||||
14-Day RSI | 44.49 | |||||
6-1 Month Momentum % | 9.47 | |||||
12-1 Month Momentum % | -9.96 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.64 | |||||
Quick Ratio | 1.23 | |||||
Cash Ratio | 0.76 | |||||
Days Inventory | 426.34 | |||||
Days Sales Outstanding | 78.86 | |||||
Days Payable | 132.14 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.3 | |||||
Shareholder Yield % | -23.92 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 82.52 | |||||
Operating Margin % | -26.85 | |||||
Net Margin % | -37.98 | |||||
FCF Margin % | -30.07 | |||||
ROE % | -362.12 | |||||
ROA % | -18.92 | |||||
ROIC % | -20.72 | |||||
ROC (Joel Greenblatt) % | -158.72 | |||||
ROCE % | -15.02 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.59 | |||||
EV-to-EBIT | -11.72 | |||||
EV-to-EBITDA | -18.22 | |||||
EV-to-Revenue | 2.64 | |||||
EV-to-Forward-Revenue | 2.33 | |||||
EV-to-FCF | -8.78 | |||||
Earnings Yield (Greenblatt) % | -8.53 | |||||
FCF Yield % | -17.59 |